However, these mutations are enriched in ER+ metastatic tumor samples from patients with acquired endocrine resistance (30–40% of ER+ patients), mostly following failure of an aromatase inhibitor-based intervention (113). The gene discussed is ESR1; the disease is metastatic neoplasm.